Can I Take 5-HTP with Evenity (Romosozumab)?

What Is Romosozumab and Who Takes It?

Romosozumab (brand name Evenity) is a sclerostin-inhibiting monoclonal antibody approved by the FDA in April 2019 for the treatment of osteoporosis in postmenopausal women at high risk of fracture. It works by blocking sclerostin, a protein that suppresses bone formation, which allows the body to build new bone while also modestly slowing bone resorption.

How the drug works in postmenopausal women

After menopause, estrogen withdrawal accelerates bone loss dramatically. Data from the FRAME trial showed that 12 monthly injections of romosozumab 210 mg subcutaneously reduced new vertebral fractures by 73% compared with placebo at 12 months in postmenopausal women. Bone mineral density (BMD) at the lumbar spine increased by a mean of 13.3% over that same period.

Romosozumab is a large-molecule biologic given by injection. It does not cross the blood-brain barrier to any clinically meaningful degree, does not bind serotonin receptors, and has no known serotonergic activity.

Who is prescribed Evenity?

The FDA label specifies postmenopausal women. The drug has not been studied in premenopausal women with osteoporosis, men (in the US approval), or women of reproductive age. If you are postmenopausal and your clinician has recommended Evenity, you may also be taking other medications common in this life stage, including antidepressants, which is exactly where 5-HTP becomes relevant to discuss.

What Is 5-HTP and Why Do Women Take It?

5-hydroxytryptophan (5-HTP) is a naturally occurring amino acid and direct precursor to serotonin. It is derived from the seeds of the West African plant Griffonia simplicifolia and sold over the counter as a supplement in doses typically ranging from 50 mg to 300 mg per day.

Reasons women use 5-HTP

Women take 5-HTP for several overlapping reasons tied to hormonal and mood changes across life stages.

• Perimenopausal and postmenopausal mood changes. Serotonin signaling shifts as estrogen declines, and some women seek 5-HTP as a non-prescription option for low mood, anxiety, or poor sleep.
• Sleep disruption. 5-HTP is a precursor to melatonin as well as serotonin, and some users take it at bedtime for insomnia.
• Appetite and weight. Small trials suggest 5-HTP may reduce carbohydrate intake; a 12-week randomized crossover study in overweight women found 5-HTP (750 mg/day) reduced caloric intake and promoted satiety.
• Fibromyalgia symptom relief. A 1990 study in the Journal of International Medical Research found 5-HTP reduced pain, fatigue, and morning stiffness scores in fibromyalgia patients.

Because postmenopausal women are the primary Evenity population, and because postmenopausal women are also among the highest users of both antidepressants and mood-support supplements, the question of 5-HTP safety with romosozumab comes up clinically.

The Pharmacokinetics: Does 5-HTP Change How Romosozumab Behaves in Your Body?

No. Pharmacokinetic (PK) interaction means one substance changes the absorption, distribution, metabolism, or excretion of another. This is extremely unlikely between these two agents.

Why PK interaction is not a concern

Romosozumab is a monoclonal antibody with a molecular weight of approximately 136 kDa. It is not metabolized by cytochrome P450 (CYP) enzymes. FDA pharmacology review data confirm that romosozumab is catabolized through standard antibody proteolytic pathways, independent of hepatic CYP enzymes or intestinal transporters.

5-HTP is absorbed from the gut, crosses the blood-brain barrier, and is metabolized by aromatic L-amino acid decarboxylase (AADC) to serotonin. This pathway does not intersect with antibody catabolism. There is no shared enzyme, transporter, or binding site between the two agents.

The practical conclusion: 5-HTP will not alter romosozumab blood levels, half-life (approximately 6.9 days for romosozumab), or bone-forming efficacy.

The Pharmacodynamic Question: Serotonin Syndrome Risk

This is the real clinical concern, and it does not involve romosozumab directly. Serotonin syndrome is a potentially serious drug-drug or drug-supplement interaction that occurs when serotonergic activity in the central and peripheral nervous systems becomes excessive.

What serotonin syndrome looks like

The Hunter Serotonin Toxicity Criteria define serotonin toxicity by the triad of neuromuscular abnormalities (clonus, hyperreflexia, tremor), autonomic instability (fever, tachycardia, diaphoresis), and altered mental status. Mild cases may present only as restlessness, tachycardia, and diaphoresis. Severe cases can include hyperthermia above 41°C and are medical emergencies.

Where 5-HTP fits into the risk picture

5-HTP raises serotonin synthesis. When combined with drugs that block serotonin reuptake (SSRIs, SNRIs), inhibit serotonin breakdown (MAO inhibitors), or directly stimulate serotonin receptors (certain triptans, tramadol), the combination may push serotonin activity past a safe threshold.

Published case reports document serotonin toxicity from 5-HTP combined with carbidopa and other serotonergic agents. The Natural Medicines database rates the interaction between 5-HTP and serotonergic drugs as a "moderate" to "major" concern depending on specific combination, a classification that does not apply to 5-HTP plus romosozumab alone because romosozumab has no serotonergic mechanism.

The clinical scenario that does create risk

Many postmenopausal women on romosozumab are also taking an SSRI or SNRI for depression, anxiety, hot flashes, or vasomotor symptoms. Approximately 23% of women aged 60 and older in the United States reported antidepressant use in NCHS data. If you are in that group, adding 5-HTP on top of an existing SSRI creates a real pharmacodynamic risk independent of romosozumab.

The correct question to ask your prescriber is therefore not "does 5-HTP interact with Evenity?" but "does 5-HTP interact with everything I take?" Romosozumab itself is not the problem. Your concurrent serotonergic medications are.

Bone Health, Serotonin, and a Nuance Worth Knowing

Serotonin itself has a lesser-known role in bone metabolism. Gut-derived serotonin (peripheral serotonin, produced by enterochromaffin cells) acts as an inhibitor of osteoblast proliferation. Research published in Cell by Yadav and colleagues demonstrated that gut-derived serotonin suppresses bone formation through the Lrp5 pathway. Blocking peripheral serotonin synthesis increased bone mass in mouse models.

Central serotonin, by contrast, promotes bone formation through a different hypothalamic relay.

What does this mean for 5-HTP? Oral 5-HTP is converted to serotonin in the gut before much of it reaches the brain. Peripheral serotonin production may theoretically increase. Whether this peripheral serotonin rise meaningfully counteracts romosozumab's bone-building signal in humans has not been studied directly. No clinical trial has examined 5-HTP use alongside romosozumab or any other bone-building agent in women. This is an evidence gap. Current practice does not restrict 5-HTP on these grounds, but the biology is a reason to use the lowest effective dose of 5-HTP if bone outcomes matter to you.

SSRIs, which also raise serotonin, have been associated with lower BMD and higher fracture risk in observational data. A meta-analysis in Osteoporosis International found SSRI use was associated with a significant increase in fracture risk (RR approximately 1.72). Whether 5-HTP supplementation carries a comparable bone risk is unknown. The data simply do not exist.

Pregnancy, Lactation, and Contraception: Required Reading

Romosozumab is contraindicated in pregnancy. This is stated plainly in the FDA-approved Evenity prescribing information. Animal studies showed fetal harm at doses producing exposures lower than those in humans. Because osteoporosis treatment with romosozumab is indicated specifically for postmenopausal women, pregnancy is not expected in this population. However, if you are a younger woman who has been prescribed romosozumab off-label for premenopausal osteoporosis (an uncommon but not unheard-of scenario, for example in women with glucocorticoid-induced or oncology-related bone loss), you must use effective contraception during treatment.

Lactation data are absent. No studies have examined romosozumab transfer into human breast milk. Given that this drug is indicated for postmenopausal women, lactation data were not gathered in development. Because it is a large-molecule monoclonal antibody, gut absorption by a nursing infant would likely be minimal, but the FDA label does not support breastfeeding during treatment. Discuss with your clinician if this scenario is relevant.

5-HTP in pregnancy and lactation. Human safety data for 5-HTP during pregnancy and breastfeeding are insufficient. No randomized controlled trials exist in pregnant or lactating women. Serotonin crosses the placenta and plays a role in fetal neurodevelopment. Until adequate data exist, 5-HTP should be avoided in pregnancy and during breastfeeding, consistent with guidance from Natural Medicines (subscription source) and general precautionary principles for serotonergic agents in pregnancy.

Life-Stage Considerations Across the Female Lifespan

Reproductive years (18 to approximately 45)

Premenopausal osteoporosis is uncommon but occurs in women with amenorrhea (from hypothalamic dysfunction, eating disorders, or hyperprolactinemia), glucocorticoid use, or genetic conditions. Romosozumab is not FDA-approved in premenopausal women and has minimal trial data in this group. 5-HTP use in reproductive-age women is more common for mood and sleep support. The serotonin syndrome caveat with concurrent SSRIs applies here too.

Perimenopause (typically 45 to 52)

Bone loss accelerates in the two to three years around the final menstrual period. Estrogen therapy remains the most effective pharmacologic strategy for preventing bone loss in perimenopausal women, per The Menopause Society. Romosozumab is not used in perimenopausal women with intact menses. Women in this stage often use 5-HTP for sleep disruption and mood shifts. The key check: are you also on an SSRI or SNRI? If yes, discuss 5-HTP safety with your prescriber first.

Postmenopause (the primary Evenity population)

This is the group most likely to be taking romosozumab. Postmenopausal women may be on antidepressants, have sleep disorders, and seek supplements. The interaction matrix here is the most complex. Your clinician needs your full supplement list, not just your prescription list.

Women with PCOS

PCOS is associated with lower bone turnover in some studies, though fracture risk data are mixed. Romosozumab is not typically used in PCOS management. Women with PCOS who take 5-HTP for mood or metabolic reasons should apply the same SSRI-interaction caution.

Monitoring: What to Watch For

If your prescriber determines that 5-HTP is reasonable alongside your Evenity course, practical monitoring includes the following.

Signs of serotonin excess

Even without a classic serotonin syndrome trigger, high-dose 5-HTP can cause flushing, diarrhea, and restlessness. Report any of the following promptly:

• Muscle twitching or clonus (a rhythmic involuntary contraction)
• Agitation or confusion that comes on quickly
• Racing heart, sweating, or fever without other explanation
• Severe diarrhea or abdominal cramping

These symptoms warrant immediate contact with your care team or, for severe presentations, emergency care.

Routine Evenity monitoring

Romosozumab carries a boxed warning for major adverse cardiovascular events (MACE), including myocardial infarction and stroke. The ARCH trial found a higher rate of serious CV events with romosozumab compared to alendronate in women with prior cardiovascular disease. 5-HTP does not appear to compound this CV risk, but cardiovascular monitoring during your treatment course is standard regardless.

BMD is typically reassessed by DXA after completing the 12-month romosozumab course and after transitioning to an antiresorptive agent such as denosumab or a bisphosphonate.

Who This Is Right For (and Who Should Think Twice)

Good candidate for continuing 5-HTP alongside Evenity

• Postmenopausal woman on Evenity with no concurrent serotonergic prescription medications
• Taking 5-HTP at a low dose (50 to 100 mg/day) for mild sleep support
• No personal or family history of serotonin syndrome
• Prescriber is aware of the supplement

Think carefully before combining

• You take an SSRI (fluoxetine, sertraline, escitalopram, paroxetine, citalopram) or SNRI (venlafaxine, duloxetine) at any dose
• You use tramadol, a triptan for migraines, or linezolid
• You have a history of bipolar disorder or any condition where serotonergic instability is a clinical concern
• You are taking doses of 5-HTP above 200 mg/day

Not appropriate

• Pregnant (both agents are contraindicated or lack safety data)
• Breastfeeding (insufficient safety data for either agent)
• Premenopausal women without specialist oversight for romosozumab

Practical Guidance: Having the Conversation with Your Clinician

Bring a written list of all supplements and doses to every Evenity follow-up appointment. Monoclonal antibodies like romosozumab are easy to assume "don't interact with supplements" because they work so differently from small-molecule drugs, and that assumption is mostly correct for PK interactions. The gap is pharmacodynamic interactions driven by your full medication profile, not by romosozumab itself.

Specific questions to raise:

1. "Am I taking any serotonergic medications that would make 5-HTP risky?"
2. "Is there a non-serotonergic alternative for sleep or mood that would work better during my Evenity course?"
3. "Should I stop 5-HTP before my monthly Evenity injection, or is continuous use acceptable given my drug list?"

There is no evidence-based dose-separation window for 5-HTP and romosozumab because no PK interaction exists. Timing of 5-HTP relative to your injection day does not change the risk calculation.

What the Evidence Gap Means for You

Women have historically been underrepresented in clinical trials, and the intersection of supplements with biologics is almost entirely unstudied in female-specific populations. No randomized trial has examined 5-HTP co-administration with romosozumab. No pharmacokinetic study has been published examining this pair. The reassurance that the combination is low risk comes from mechanistic reasoning (different pathways, no shared enzymes, no shared receptors) rather than from direct human trial data. That distinction is honest and you deserve to know it.

The bone-serotonin biology described above (peripheral serotonin suppressing osteoblast activity via Lrp5) is a legitimate theoretical concern that has not been examined clinically in the context of 5-HTP plus romosozumab. Until that research exists, using the lowest effective 5-HTP dose and reporting it to your Evenity prescriber is the most defensible approach.